Skip to main content
. Author manuscript; available in PMC: 2013 Aug 29.
Published in final edited form as: Breast Cancer Res Treat. 2010 Oct 26;125(1):137–143. doi: 10.1007/s10549-010-1226-z

Table 3.

Adverse events

Adverse events Grade 1 or 2 Grade 3 or 4
Hand-foot syndrome 8 (23%) 12 (34%)
Fatigue 17 (49%) 6 (17%)
Rash 13 (37%) 4 (11%)
Emesis 10 (29%) 4 (11%)
Hypertension 7 (20%) 4 (11%)
Nausea 18 (51%) 3 (9%)
Arthralgias 6 (17%) 3 (9%)
Diarrhea 20 (57%) 2 (6%)
Dehydration 1 (3%) 2 (6%)
Infection 1 (3%) 2 (6%)
Anorexia 10 (29%) 1 (3%)
Headache 8 (23%) 1 (3%)
Mucositis 7 (20%) 1 (3%)
Elevated liver function tests 6 (17%) 1 (3%)
Rigors/chills 4 (11%) 1 (3%)
Joint function 3 (9%) 1 (3%)
Neutropenia 2 (6%) 1 (3%)
Dyspnea 2 (6%) 1 (3%)
Acne 1 (3%) 1 (3%)
Hypotension 1 (3%) 1 (3%)
Hypophosphatemia 0 1 (3%)
Thrombosis 0 1 (3%)
Urticaria 0 1 (3%)
Pleural effusion 0 1 (3%)
Alopecia 18 (51%) 0
Pain—other 17 (48%) 0
Constipation 10 (29%) 0
Pruritus/itching 10 (29%) 0
Sensory neuropathy 9 (26%) 0
Weight loss 9 (26%) 0